Back
Intellia Therapeutics, Inc. 10K Form
Sell
34
NTLA
Intellia Therapeutics, Inc.
Last Price:
$13.82
Seasonality Move:
0.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NTLA News And Ratings
See the #1 stock for the next 7 days that we like better than NTLA
NTLA Financial Statistics
Sales & Book Value
| Annual Sales: | $67.7M |
|---|---|
| Cash Flow: | $-69.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $5.77 |
| Price / Book: | 2.35 |
Profitability
| EPS (TTM): | -3.82660 |
|---|---|
| Net Income (TTM): | $-412.7M |
| Gross Margin: | $51.7M |
| Return on Equity: | -54.49% |
| Return on Assets: | -42.6% |
Intellia Therapeutics, Inc. Earnings Forecast
Key Intellia Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 12 years for NTLA is 76.47%.
-
The Selling, General & Administrative Expenses for NTLA have been equal to 177.03% of Gross Profit Margin.
-
The Research & Development expenses have been 560.20% of Revenue.
-
The Net Earning history of NTLA is -609.85% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 4 years.
Intellia Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NTLA |
| CUSIP: | 45826J |
| Website: | intelliatx.com |
Debt
| Debt-to-Equity Ratio: | 0.14 |
|---|---|
| Current Ratio: | 5.08 |
| Quick Ratio: | 4.42 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NTLA Technical Analysis vs Fundamental Analysis
Sell
34
Intellia Therapeutics, Inc. (NTLA)
is a Sell
Is Intellia Therapeutics, Inc. a Buy or a Sell?
-
Intellia Therapeutics, Inc. stock is rated a SellThe current Intellia Therapeutics, Inc. [NTLA] share price is $13.61. The Score for NTLA is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.